30 July 2018
Genentech has dosed the first patient in a Phase 3 study of a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) for subcutaneous administration using US-based biotechnology firm Halozyme's proprietary...
10 July 2018
Researchers from Lehigh University in the US have designed a new possible solution for antibiotic resistant bacteria by combining antibiotics with the exploitation of the body’s immune response.
21 May 2018
AstraZeneca has announced a collaboration with Emulate to develop and embed the start-up’s Organs-on-Chips technology within its Innovative Medicines and Early Development (IMED) Drug Safety organisation laboratories.
16 May 2018
Local Intelligent Drug Delivery System (LIDDS) has verified its NanoZolid technology as a subcutaneous depot for systemic delivery of pharmaceutically active drugs, intended to revolutionise the administration of cancer treatments.
4 May 2018
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended three medications for approval during its April meeting, and Drug development company Proniras has entered...
16 April 2018
Researchers from Massachusetts Institute of Technology (MIT) and the Catholic University of Brasilia have developed a computer algorithm to develop antimicrobial peptides that kill microbes more effectively than peptides synthesised...
11 April 2018
Researchers from Austrian university TU Wien and international pharmaceutical company Sandoz have developed a computer simulation that replicates the growth behaviour of penicillin-producing organisms, enabling drug production to continue without...
7 March 2018
Researchers from the University of Warwick have developed a way to control the distribution of ribosomes in bacteria, which could enable scientists to program them to produce drugs.
1 March 2018
Phenomics company Median Technologies and Japanese contract research organisation (CRO) CMIC Holdings have announced a collaboration to provide more comprehensive clinical trial services.
28 February 2018
Pharmaceutical company Lantern Pharma, known for its work in precision oncology using artificial intelligence (AI), has joined Genomics England’s drug discovery alliance.